ASND Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

245.15M

+40.96%

-0.143

-77.7%

275.88M

+173.27%

0.400

-125.32%

310.11M

+96.22%

0.681

-206.45%

Estimates Revision

The market is revising Downward the revenue expectations for Ascendis Pharma A/S (ASND) for FY2025, with the revenue forecasts being adjusted by -1.18% over the past three months. During the same period, the stock price has changed by -3.13%.

Revenue Estimates for FY2025

Revise Downward

-1.18%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+24.44%

In Past 3 Month

Stock Price

Go Down

-3.13%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 260.46 USD with a low forecast of 220.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

220.00

Averages

260.46

High

325.00

Current: 0.000

Low

220.00

Averages

260.46

High

325.00

Wells Fargo

Overweight

maintain

$297 -> $322

2026-01-09

New

Reason

Wells Fargo

Price Target

$297 -> $322

2026-01-09

New

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Ascendis Pharma to $322 from $297 and keeps an Overweight rating on the shares. The firm believes shares should trade up about 10% as the 52-week COACH data resets the bar higher in achondroplasia, with the combo likely to drive higher market share for TransCon CNP. Wells' estimates move up, and the TransCon CNP+Skytrofa combo is likely to become the standard of care over time.

Stifel

Alex Thompson

Buy

maintain

$254 -> $256

2025-12-11

Reason

Stifel

Alex Thompson

Price Target

$254 -> $256

2025-12-11

maintain

Buy

Reason

Stifel analyst Alex Thompson raised the firm's price target on Ascendis Pharma to $256 from $254 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.

Wolfe Research

Outperform

initiated

$255

2025-11-17

Reason

Wolfe Research

Price Target

$255

2025-11-17

initiated

Outperform

Reason

Wolfe Research initiated coverage of Ascendis Pharma with an Outperform rating and $255 price target. Yorvipath is off to a "strong" launch and "the party is only beginning," according to the analyst, who sees $4B-pluse peak sales "looking increasingly achievable." The stock looks priced as if Yorvipath is the whole story, leaving the derisked pipeline looking "underappreciated," the analyst added.

BofA

Tazeen Ahmad

Buy

maintain

$230 -> $242

2025-10-20

Reason

BofA

Tazeen Ahmad

Price Target

$230 -> $242

2025-10-20

maintain

Buy

Reason

BofA analyst Tazeen Ahmad raised the firm's price target on Ascendis Pharma to $242 from $230 and keeps a Buy rating on the shares. The firm's survey of 26 endocrinologists who treat HPT patients on Yorvipath indicates growing uptake in Q3, says the analyst, who is "encouraged" by the continued positive real-world outlook for Yorvipath usage and looks for updated commentary from the company on payor coverage and trending discontinuation rate on the earnings call.

RBC Capital

Luca Issi

Outperform

maintain

2025-10-20

Reason

RBC Capital

Luca Issi

Price Target

2025-10-20

maintain

Outperform

Reason

RBC Capital analyst Luca Issi says the firm has received a number of inbounds on the Ascendis Pharma stock weakness and a few have pointed out the death reported on the FDA Adverse Event Reporting System database. It looks like the patient passed on August 22nd and that such patient had HER2+ breast cancer and hypoparathyroidism. Initial FDA received date is October 3rd and latest received data was yesterday, the firm notes. This is the first death reported on the FAERS database. RBC thinks this is another reminder that looking at the FAERS database has multiple limitations as it is often difficult to distinguish causation vs correlation. Details are sparse and difficult to be definitive, but the firm believes this is likely an example of the latter given a complex clinical picture, multiple concomitant medications and while the cause of death remains unknown, breast cancer can be fatal. Overall, the firm is not worried about this case and remains a buyer of Outperform-rated Ascendis.

Raymond James

Martin Auster

Strong Buy

initiated

$271

2025-10-16

Reason

Raymond James

Martin Auster

Price Target

$271

2025-10-16

initiated

Strong Buy

Reason

Raymond James analyst Martin Auster initiated coverage of Ascendis Pharma with a Strong Buy rating and $271 price target. The firm sees "a high conviction path" to 2035 total revenues of about $4.6B - including $3.3B for Yorvipath for hypoparathyroidism, $750M for TransCon CNP for achondroplasia and $550M for Skytrofa - as well as "a range of credible upside scenarios," the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Ascendis Pharma A/S (ASND.O) is 94.95, compared to its 5-year average forward P/E of -3.60. For a more detailed relative valuation and DCF analysis to assess Ascendis Pharma A/S 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.60

Current PE

94.95

Overvalued PE

47.78

Undervalued PE

-54.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.88

Current EV/EBITDA

95.32

Overvalued EV/EBITDA

50.52

Undervalued EV/EBITDA

-62.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

112.73

Current PS

9.51

Overvalued PS

326.60

Undervalued PS

-101.15

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 565.41% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ASND News & Events

Events Timeline

No data

News

7.0

01-09Globenewswire

Ascendis Pharma Updates 2026 Strategic Roadmap, Projects €683 Million Revenue

9.0

01-09NASDAQ.COM

Ascendis Pharma Reports Positive Phase 2 Results for Pediatric Achondroplasia Treatment

3.0

2025-12-21Yahoo Finance

Evaluating Ascendis Pharma's 2025 Valuation Following Significant Gains and DCF Growth Potential

People Also Watch

Frequently Asked Questions

What is Ascendis Pharma A/S (ASND) stock price today?

The current price of ASND is 202.99 USD — it has decreased -2.76 % in the last trading day.

What is Ascendis Pharma A/S (ASND)'s business?

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

What is the price predicton of ASND Stock?

What is Ascendis Pharma A/S (ASND)'s revenue for the last quarter?

Ascendis Pharma A/S revenue for the last quarter amounts to 213.63M USD, increased 269.40 % YoY.

What is Ascendis Pharma A/S (ASND)'s earnings per share (EPS) for the last quarter?

Ascendis Pharma A/S. EPS for the last quarter amounts to -1.00 USD, decreased -41.86 % YoY.

What changes have occurred in the market's expectations for Ascendis Pharma A/S (ASND)'s fundamentals?

How many employees does Ascendis Pharma A/S (ASND). have?

Ascendis Pharma A/S (ASND) has 879 emplpoyees as of January 10 2026.

What is Ascendis Pharma A/S (ASND) market cap?

Today ASND has the market capitalization of 12.52B USD.